<DOC>
	<DOC>NCT01826916</DOC>
	<brief_summary>EDEMA2 is an open-label, Phase 2 dose-ranging study designed to assess the safety and efficacy of repeated dosing of DX-88 (recombinant plasma kallikrein inhibitor) in Patients with Hereditary Angioedema.</brief_summary>
	<brief_title>EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas, Hereditary</mesh_term>
	<criteria>10 years of age or older Documented diagnosis of HAE (Type I or II) Patient reported to a study site no later than 4 hours following patient recognition of the onset of the attack Willing and able to give informed consent Patients with a serious intercurrent illness or serious active infection Patient with serum creatinine greater than 110% the upper limit of normal or liver transaminases 2 times the upper limit of normal Receipt of an investigational drug or device, within 30 days prior to study treatment Pregnancy or breastfeeding Diagnosis of acquired angioedema (AAE) Patients who had not completed their Day7 followup procedures for a previously treated attack</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>